These observations draw attention to the importance of effective neutropenia management in patients receiving SACT and that appropriate use of G-CSF in the context of primary or secondary prophylaxis correlates with clinically meaningful improvements in patient outcomes. The gene discussed is CSF3; the disease is neutropenia.